Received Mar 20, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAP | DTAP (INFANRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | TX77L-VFC | IM / RL |
| HEPA | HEP A (VAQTA) | MERCK & CO. INC. | 1 | Y008285-VFC | IM / RL |
| HIBV | HIB (HIBERIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 53472-VFC | IM / LL |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | 1 | Y009108-VFC | IM / LL |
| PNC20 | PNEUMO (PREVNAR20) | PFIZER\WYETH | 3 | HR3649-VFC | IM / RL |
Presented to ER for evaluation on 3/20/2025 at 7:18 AM with report of "rash." Child was evaluated by the ER physician and received oral cetirizine and acetaminophen. Child was discharged in stable condition. Family presented to the office with child to report potential reaction to vaccinations. Reported the child had facial swelling upon awakening that morning, greater than 12 hours following vaccination administration.
Cold symptoms on 3/17/25.
None.
None.
None.
None.